Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DepoDur (extended-release epidural morphine)
DepoDur · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | No test dose + DepoDur + flush with 1 mL normal saline |
| 2 | EXPERIMENTAL | Test dose + flush with 1 mL normal saline + 3-minute wait + DepoDur + flush with 1 mL normal saline |
| 3 | EXPERIMENTAL | Test dose + flush with 1 mL normal saline + 10-minute wait + DepoDur + flush with 1 mL normal saline |
| 4 | EXPERIMENTAL | Test dose + flush with 1 mL normal saline + 15-minute wait + DepoDur + flush with 1 mL normal saline |
| 5 | EXPERIMENTAL | Test dose + No flush + 3-minute wait + DepoDur + flush with 1 mL normal saline |
| Name | Type | Description |
|---|---|---|
| DepoDur (extended-release epidural morphine) | DRUG | DepoDur with on demand boluses of IV fentanyl PCA |
Inclusion Criteria: * Males and females ≥ 18 years of age at Screening * Negative pregnancy test in females of childbearing potential * Scheduled for major upper abdominal surgery via an upper midline incision under general anesthesia * American Society of Anesthesiology (ASA) Physical Class 1, 2, ...
DepoDur is an extended-release epidural morphine formulation developed by Pacira BioSciences, Inc. (ticker PCRX). It is a small molecule product studied for postoperative pain, designed to deliver morphine into the epidural space. It is also known as extended-release epidural morphine.
DepoDur is used for postoperative pain, meaning pain following surgery. Its clinical development has focused on managing pain after procedures such as upper abdominal surgery. It is administered as an extended-release epidural morphine formulation rather than as a conventional immediate-release morphine product.
DepoDur is developed by Pacira BioSciences, Inc., which trades under the ticker PCRX. Pacira is the company associated with the asset and its clinical development program in postoperative pain.
DepoDur is in Phase 1 development based on its recorded clinical program. It is an investigational product and is not described as approved. Its development activity in postoperative pain has centered on early-phase study rather than late-stage or registrational trials.
DepoDur has been studied in the Phase 1 trial NCT00728832, titled A Pharmacokinetic (PK) Study of Extended-Release Epidural Morphine in Upper Abdominal Surgery. That trial enrolled 39 participants, was randomized and active-controlled, and is now completed. No active trials are currently listed for DepoDur.
Yes. DepoDur is the brand name for extended-release epidural morphine, so searches for either term refer to the same product. It is a small molecule formulation developed by Pacira BioSciences, Inc. (PCRX) and studied for postoperative pain.